Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2017
At a glance
- Drugs Afatinib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Mar 2017 Status changed from not yet recruiting to recruiting.
- 24 Feb 2017 Planned initiation date changed from 1 Dec 2016 to 1 Feb 2017.
- 05 Dec 2016 New trial record